{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:15:40Z","timestamp":1788437740890,"version":"build-2803163510"},"update-to":[{"DOI":"10.1002\/14651858.cd015123","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000}}],"reference-count":132,"publisher":"Wiley","issue":"8","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd015123.pub2","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T12:52:47Z","timestamp":1754484767000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Natalizumab for multiple sclerosis"],"prefix":"10.1002","volume":"2025","author":[{"given":"Chunyu","family":"Liu","sequence":"additional","affiliation":[{"name":"West China Medical School; West China Hospital, Sichuan University; Chengdu China"},{"name":"Department of Pharmacy\/Evidence-Based Pharmacy Center; West China Second University Hospital, Sichuan University; Chengdu China"},{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children; Sichuan University, Ministry of Education; Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaolun","family":"Cai","sequence":"additional","affiliation":[{"name":"Gastric Cancer Center, Department of General Surgery; West China Hospital, Sichuan University; Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangping","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Cardiology; The First Affiliated Hospital of Xinxiang Medical University; Xinxiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muke","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Neurology; West China Hospital, Sichuan University; Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingli","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy\/Evidence-Based Pharmacy Center; West China Second University Hospital, Sichuan University; Chengdu China"},{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children; Sichuan University, Ministry of Education; Chengdu China"},{"name":"Chinese Evidence-based Medicine Center; West China Hospital, Sichuan University; Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD015123.pub2-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41572-018-0041-4","article-title":"Multiple sclerosis","volume":"4","author":"Filippi","year":"2018","journal-title":"Nature Reviews. Disease Primers"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0002|cit2","unstructured":"The Multiple Sclerosis International Federation (MSIF) Atlas of MS, Version 3 (updated Septmber 2020). MSIF, 2020 https:\/\/atlasofms.org\/map\/global\/epidemiology\/number-of-people-with-ms"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0003|cit3","doi-asserted-by":"crossref","unstructured":"Teriflunomide for multiple sclerosis Cochrane Database of Systematic Reviews 2016 3 10.1002\/14651858.CD009882.pub3","DOI":"10.1002\/14651858.CD009882.pub3"},{"issue":"3","key":"10.1002\/14651858.CD015123.pub2-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD015123.pub2-BIB0005|cit5","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011381.pub3","article-title":"Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis","author":"Gonzalez-Lorenzo","year":"2024","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD015123.pub2-BIB0006|cit6","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015443.pub2","article-title":"Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta-analysis","author":"Ridley","year":"2024","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD015123.pub2-BIB0007|cit7","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012186.pub2","article-title":"Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis","author":"Tramacere","year":"2023","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12","key":"10.1002\/14651858.CD015123.pub2-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"a029066","DOI":"10.1101\/cshperspect.a029066","article-title":"Natalizumab: perspectives from the bench to bedside","volume":"8","author":"Shirani","year":"2018","journal-title":"Cold Spring Harbor Perspectives in Medicine"},{"issue":"7","key":"10.1002\/14651858.CD015123.pub2-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40265-013-0030-6","article-title":"Drugs in development for relapsing multiple sclerosis","volume":"73","author":"Ali","year":"2013","journal-title":"Drugs"},{"issue":"9","key":"10.1002\/14651858.CD015123.pub2-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1177\/1756285617716002","article-title":"The role of natalizumab in the treatment of multiple sclerosis: benefits and risks","volume":"10","author":"Singer","year":"2017","journal-title":"Therapeutic Advances in Neurological Disorders"},{"issue":"1","key":"10.1002\/14651858.CD015123.pub2-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1527-3458.2007.00003.x","article-title":"Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri\u00ae) in inflammatory diseases","volume":"13","author":"St\u00fcve","year":"2007","journal-title":"CNS Drug Reviews"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0012|cit12","unstructured":"Bryan WW; Center for Drug Evaluation and Research Clinical Review BLA 125104\/0 Tysabri (natalizumab) www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2004\/125104s000_Natalizumab_Medr_P1.pdf"},{"issue":"9","key":"10.1002\/14651858.CD015123.pub2-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD015123.pub2-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00415-009-0093-1","article-title":"The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL","volume":"256","author":"Hutchinson","year":"2009","journal-title":"Journal of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD015123.pub2-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/archneurol","article-title":"Efficacy of natalizumab therapy in patients of African descent with relapsing multiple sclerosis: analysis of AFFIRM and SENTINEL data","volume":"68","author":"Cree","year":"2011","journal-title":"Archives of Neurology"},{"issue":"3","key":"10.1002\/14651858.CD015123.pub2-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/S1474-4422(09)70021-3","article-title":"Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study","volume":"8","author":"Havrdova","year":"2009","journal-title":"Lancet. Neurology"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0017|cit17","unstructured":"Safety and efficacy of natalizumab in the treatment of multiple sclerosis clinicaltrials.gov\/study\/NCT00027300"},{"issue":"4","key":"10.1002\/14651858.CD015123.pub2-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/ana.21163","article-title":"Health-related quality of life in multiple sclerosis: effects of natalizumab","volume":"62","author":"Rudick","year":"2007","journal-title":"Annals of Neurology"},{"issue":"17","key":"10.1002\/14651858.CD015123.pub2-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"1390-401","DOI":"10.1212\/01.wnl.0000260064.77700.fd","article-title":"MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS","volume":"68","author":"Miller","year":"2007","journal-title":"Neurology"},{"issue":"10","key":"10.1002\/14651858.CD015123.pub2-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"S219","DOI":"10.1177\/1352458511422300","article-title":"Long-term outcomes in natalizumab-treated patients who were free of disease activity over the 2-year AFFIRM study","volume":"17","author":"Rudick","year":"2011","journal-title":"Multiple Sclerosis Journal"},{"issue":"11","key":"10.1002\/14651858.CD015123.pub2-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1177\/1352458513502429","article-title":"Effects of natalizumab treatment on freedom from disease activity by baseline characteristics in AFFIRM","volume":"19","author":"Havrdova","year":"2013","journal-title":"Multiple Sclerosis Journal"},{"issue":"5","key":"10.1002\/14651858.CD015123.pub2-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1007\/s00415-012-6809-7","article-title":"Clinical effects of natalizumab on multiple sclerosis appear early in treatment course","volume":"260","author":"Kappos","year":"2013","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"119-24","DOI":"10.1016\/j.jns.2012.03.009","article-title":"Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing MS","volume":"318","author":"Balcer","year":"2012","journal-title":"Journal of the Neurological Sciences"},{"issue":"1","key":"10.1002\/14651858.CD015123.pub2-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1177\/1352458514546077","article-title":"Natalizumab decreases progression of disability in RRMS patients as measured by the composite EDSSPlus in AFFIRM","volume":"20","author":"Dong","year":"2014","journal-title":"Multiple Sclerosis Journal"},{"issue":"6","key":"10.1002\/14651858.CD015123.pub2-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1177\/1352458514563659","article-title":"Quantifying the effect of natalizumab on the total disability burden of MS patients in AFFIRM using an exploratory area under the curve analysis","volume":"21","author":"Belachew","year":"2015","journal-title":"Multiple Sclerosis Journal"},{"issue":"5","key":"10.1002\/14651858.CD015123.pub2-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1007\/s00415-011-6275-7","article-title":"Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS","volume":"259","author":"Weinstock-Guttman","year":"2012","journal-title":"Journal of Neurology"},{"issue":"1","key":"10.1002\/14651858.CD015123.pub2-BIB0027|cit27","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1136\/jnnp-2011-300279","article-title":"Treatment effect of natalizumab on relapse outcomes in multiple sclerosis patients despite ongoing MRI activity","volume":"83","author":"Bates","year":"2012","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry Research"},{"issue":"14","key":"10.1002\/14651858.CD015123.pub2-BIB0028|cit28","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1212\/01.wnl.0000277457.17420.b5","article-title":"The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL","volume":"69","author":"Calabresi","year":"2007","journal-title":"Neurology"},{"issue":"6","key":"10.1002\/14651858.CD015123.pub2-BIB0029|cit29","doi-asserted-by":"publisher","first-page":"705-11","DOI":"10.1016\/j.msard.2014.08.005","article-title":"Natalizumab reduces relapse clinical severity and improves relapse recovery in MS","volume":"3","author":"Lublin","year":"2014","journal-title":"Multiple Sclerosis and Related Disorders"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/j.1468-1331.2011.03551.x","article-title":"Evaluation of a multiple sclerosis (MS) disease progression composite (EXPANDED disability status scale [EDSS], Ms functional composite [msfc], and lowcontrast letter acuity [LCA])","volume":"18","author":"Balcer","year":"2011","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"P7.244","DOI":"10.1212\/WNL.84.14_supplement.P7.244","article-title":"Natalizumab reduces total disability burden relative to placebo in patients with relapsing-remitting multiple sclerosis regardless of the occurrence of relapses or confirmed disability progression or improvement over 2 years in the AFFIRM study","volume":"84","author":"Giovannoni","year":"2015","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0032|cit32","unstructured":"FDA drug safety communication: risk of progressive multifocal leukoencephalopathy (PML) with the use of Tysabri (natalizumab) www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/fda-drug-safety-communication-risk-progressive-multifocal-leukoencephalopathy-pml-use-tysabri"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0033|cit33","unstructured":"FDA drug safety communication: safety update on progressive multifocal leukoencephalopathy (PML) associated with Tysabri (natalizumab) www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-safety-update-progressive-multifocal-leukoencephalopathy-pml"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0034|cit34","unstructured":"FDA drug safety communication: new risk factor for progressive multifocal leukoencephalopathy (PML) associated with Tysabri (natalizumab) www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-new-risk-factor-progressive-multifocal-leukoencephalopathy-pml"},{"issue":"3","key":"10.1002\/14651858.CD015123.pub2-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1179\/016164106X98198","article-title":"Progressive multifocal leukoencephalopathy: lessons from AIDS and natalizumab","volume":"28","author":"Berger","year":"2006","journal-title":"Neurological Research"},{"issue":"20","key":"10.1002\/14651858.CD015123.pub2-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD015123.pub2-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S1474-4422(18)30040-1","article-title":"Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned","volume":"17","author":"Major","year":"2018","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"549842","DOI":"10.3389\/fimmu.2020.549842","article-title":"Natalizumab in multiple sclerosis treatment: from biological effects to immune monitoring","volume":"11","author":"Khoy","year":"2020","journal-title":"Frontiers in Immunology"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0039|cit39","unstructured":"European Medicines Agency Tysabri www.ema.europa.eu\/en\/medicines\/human\/referrals\/tysabri#key-facts-section"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0040|cit40","unstructured":"European Medicines Agency Plegridy : EPAR - Product Information www.ema.europa.eu\/en\/documents\/product-information\/plegridy-epar-product-information_en.pdf"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0041|cit41","unstructured":"European Medicines Agency Tysabri: EPAR - Product information www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tysabri#product-information-section"},{"issue":"10","key":"10.1002\/14651858.CD015123.pub2-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1002\/jcph.707","article-title":"A randomized trial evaluating various administration routes of natalizumab in multiple sclerosis","volume":"56","author":"Plavina","year":"2016","journal-title":"Journal of Clinical Pharmacology"},{"issue":"14","key":"10.1002\/14651858.CD015123.pub2-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1177\/13524585211003020","article-title":"A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis","volume":"27","author":"Trojano","year":"2021","journal-title":"Multiple Sclerosis Journal"},{"issue":"5","key":"10.1002\/14651858.CD015123.pub2-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1007\/s40120-024-00647-0","article-title":"Patient preference for subcutaneous versus intravenous administration with every-6-week natalizumab (tysabri\u00ae) dosing: NOVA phase iiib extension study (part 2)","volume":"13","author":"Wiendl","year":"2024","journal-title":"Neurology and Therapy"},{"issue":"17_supplement_2","key":"10.1002\/14651858.CD015123.pub2-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1212\/WNL.0000000000202006","article-title":"Natalizumab extended interval dosing (EID) is associated with a reduced risk of progressive multifocal leukoencephalopathy (PML) compared with every-4-week (Q4W) dosing: updated analysis of the TOUCH\u00ae prescribing program database (P14-3.011)","volume":"100","author":"Ryerson","year":"2023","journal-title":"Neurology"},{"issue":"7","key":"10.1002\/14651858.CD015123.pub2-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/S1474-4422(22)00143-0","article-title":"Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial","volume":"21","author":"Foley","year":"2022","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"103995","DOI":"10.1016\/j.msard.2022.103995","article-title":"Use of natalizumab in persons with multiple sclerosis: 2022 update","volume":"65","author":"Morrow","year":"2022","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"17","key":"10.1002\/14651858.CD015123.pub2-BIB0048|cit48","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","article-title":"Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology","volume":"90","author":"Rae-Grant","year":"2018","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0049|cit49","doi-asserted-by":"publisher","first-page":"101459","DOI":"10.1016\/j.msard.2019.101459","article-title":"Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines","volume":"37","author":"Yamout","year":"2020","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"10","key":"10.1002\/14651858.CD015123.pub2-BIB0050|cit50","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007621.pub2","article-title":"Natalizumab for relapsing remitting multiple sclerosis","author":"Pucci","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD015123.pub2-BIB0051|cit51","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015123","article-title":"Natalizumab for multiple sclerosis","author":"Liu","year":"2022","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0052|cit52","unstructured":"Higgins JP Lasserson T Thomas J Flemyng E Churchill R Methodological Expectations of Cochrane Intervention Reviews. Cochrane: London, Version August 2023 Available from https:\/\/community.cochrane.org\/mecir-manual"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD015123.pub2-BIB0054|cit54","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/ana.410130302","article-title":"New diagnostic criteria for multiple sclerosis: guidelines for research protocols","volume":"13","author":"Poser","year":"1983","journal-title":"Annals of Neurology"},{"issue":"1","key":"10.1002\/14651858.CD015123.pub2-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/ana.1032","article-title":"Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis","volume":"50","author":"McDonald","year":"2001","journal-title":"Annals of Neurology"},{"issue":"6","key":"10.1002\/14651858.CD015123.pub2-BIB0056|cit56","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/ana.20703","article-title":"Diagnostic criteria for multiple sclerosis: 2005 revisions to the McDonald criteria","volume":"58","author":"Polman","year":"2005","journal-title":"Annals of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD015123.pub2-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Annals of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD015123.pub2-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurology"},{"issue":"4","key":"10.1002\/14651858.CD015123.pub2-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1212\/wnl.46.4.907","article-title":"Defining the clinical course of multiple sclerosis: results of an international survey","volume":"46","author":"Lublin","year":"1996","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD015123.pub2-BIB0060|cit60","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1177\/1352458512457841","article-title":"Sormani MP, Signori A, Siri P, De Stefano N. Time to first relapse as an endpoint in multiple sclerosis clinical trials","volume":"19","author":"Sormani","year":"2013","journal-title":"Multiple Sclerosis Journal"},{"issue":"22","key":"10.1002\/14651858.CD015123.pub2-BIB0061|cit61","doi-asserted-by":"publisher","first-page":"e2538","DOI":"10.1212\/WNL.0000000000008186","article-title":"Clinical trials of disease-modifying agents in pediatric MS: Opportunities, challenges, and recommendations from the IPMSSG","volume":"92","author":"Waubant","year":"2019","journal-title":"Neurology"},{"issue":"11","key":"10.1002\/14651858.CD015123.pub2-BIB0062|cit62","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/wnl.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"11","key":"10.1002\/14651858.CD015123.pub2-BIB0063|cit63","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1001\/archneurol.2010.150","article-title":"Disability progression in a clinical trial of relapsing-remitting multiple sclerosis: eight-year follow-up","volume":"67","author":"Rudick","year":"2010","journal-title":"Archives of Neurology"},{"issue":"6","key":"10.1002\/14651858.CD015123.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Sherbourne","year":"1992","journal-title":"Medical Care"},{"issue":"Pt 5","key":"10.1002\/14651858.CD015123.pub2-BIB0065|cit65","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1093\/brain\/124.5.962","article-title":"The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure","volume":"124","author":"Hobart","year":"2001","journal-title":"Brain"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0066|cit66","unstructured":"Lefebvre C Glanville J Briscoe S Featherstone R Littlewood A Chapter 4: Searching for and selecting studies [last updated September 2024]. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024 Available from https:\/\/www.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0067|cit67","unstructured":"Covidence Veritas Health Innovation 2024"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0068|cit68","unstructured":"EndNote\u2122 Clarivate 2018"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0069|cit69","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2024"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0070|cit70","unstructured":"Engauge Digitizer Software Mark M Baurzhan M Tobias W Wilms A van Schaik B Mark Mitchell 2019 10.5281\/zenodo.3558440"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0071|cit71","unstructured":"WebPlotDigitizer Rohatgi A Ankit Rohatgi 2020"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0072|cit72","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0073|cit73","unstructured":"Higgins JPT Savovi\u0107 J Page MJ Elbers RG Sterne JAC Chapter 8: Assessing risk of bias in a randomized trial [last updated October 2019]. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024 Available from https:\/\/www.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0074|cit74","doi-asserted-by":"publisher","first-page":"e12031","DOI":"10.1002\/cesm.12031","article-title":"Ten tips for successful assessment of risk of bias in randomized trials using the RoB 2 tool: early lessons from Cochrane","volume":"1","author":"Moore","year":"2023","journal-title":"Cochrane Evidence Synthesis and Methods"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0075|cit75","unstructured":"Sch\u00fcnemann HJ Vist GE Higgins JPT Santesso N Deeks JJ Glasziou P Chapter 15: Interpreting results and drawing conclusions [last updated August 2023]. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024 Available from https:\/\/www.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0076|cit76","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/1477-7525-8-116","article-title":"Improving the interpretation of quality of life evidence in meta-analyses: the application of minimal important difference units","volume":"8","author":"Johnston","year":"2010","journal-title":"Health and Quality of Life Outcomes"},{"issue":"13","key":"10.1002\/14651858.CD015123.pub2-BIB0077|cit77","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1177\/1352458514530489","article-title":"Responder definition of the Multiple Sclerosis Impact Scale physical impact subscale for patients with physical worsening","volume":"20","author":"Phillips","year":"2014","journal-title":"Multiple Sclerosis Journal"},{"issue":"7","key":"10.1002\/14651858.CD015123.pub2-BIB0078|cit78","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40263-017-0457-5","article-title":"Health-related quality of life in patients with multiple sclerosis: impact of disease-modifying drugs","volume":"31","author":"Jongen","year":"2017","journal-title":"CNS Drugs"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0079|cit79","unstructured":"Higgins JPT Eldridge S Li T Chapter 23: Including variants on randomized trials [last updated October 2019]. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024 Available from https:\/\/www.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0080|cit80","unstructured":"Boutron I Page MJ Higgins JPT Altman DG Lundh A Hr\u00f3bjartsson A Chapter 7: Considering bias and conflicts of interest among the included studies. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v6.4"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0081|cit81","doi-asserted-by":"publisher","first-page":"16890","DOI":"10.1136\/bmj.l6890","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0082|cit82","unstructured":"Deeks JJ Higgins JPT Altman DG McKenzie JE Chapter 10: Analysing data and undertaking meta-analyses [last updated November 2024]. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024 Available from https:\/\/www.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0083|cit83","unstructured":"Sch\u00fcnemann HJ Higgins JPT Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence [last updated August 2023]. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024 Available from https:\/\/www.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0084|cit84","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime, Inc.) 2024"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0085|cit85","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/1471-2377-13-101","article-title":"Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial","volume":"13","author":"Gobbi","year":"2013","journal-title":"BMC Neurology"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0086|cit86","unstructured":"Natalizumab de-escalation to interferon-beta-1b in patients with relapsing-remitting multiple sclerosis: A multicenter study www.clinicaltrialsregister.eu\/ctr-search\/trial\/2012-004040-30\/AT"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0087|cit87","unstructured":"Natalizumab de-escalation with interferon beta-1b clinicaltrials.gov\/study\/NCT01144052"},{"issue":"4","key":"10.1002\/14651858.CD015123.pub2-BIB0088|cit88","doi-asserted-by":"publisher","first-page":"463-4","DOI":"10.1177\/1352458512459021","article-title":"Natalizumab de-escalation to interferon-b-1b in multiple sclerosis: a randomised, controlled, pilot trial","volume":"18","author":"Zecca","year":"2012","journal-title":"Multiple Sclerosis Journal"},{"issue":"10","key":"10.1002\/14651858.CD015123.pub2-BIB0089|cit89","doi-asserted-by":"publisher","first-page":"S193","DOI":"10.1177\/1352458511422300","article-title":"De-escalation after natalizumab treatment with interferon beta-1b in patients with relapsing-remitting multiple sclerosis: 6-month interim results of a pilot study","volume":"17","author":"Zecca","year":"2011","journal-title":"Multiple Sclerosis Journal"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0090|cit90","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1471-2377-14-38","article-title":"Treatment satisfaction, adherence and behavioral assessment in patients de-escalating from natalizumab to interferon \u03b2","volume":"14","author":"Zecca","year":"2014","journal-title":"BMC Neurology"},{"issue":"10","key":"10.1002\/14651858.CD015123.pub2-BIB0091|cit91","doi-asserted-by":"publisher","first-page":"e111-2","DOI":"10.1016\/j.clinph.2012.03.072","article-title":"Natalizumab de-escalation to interferon beta-1b in multiple sclerosis patients","volume":"123","author":"Zecca","year":"2012","journal-title":"Clinical Neurophysiology"},{"issue":"9","key":"10.1002\/14651858.CD015123.pub2-BIB0092|cit92","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"New England Jourmal of Medicine"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0093|cit93","unstructured":"Safety and efficacy of natalizumab in combination with avonex in the treatment of multiple sclerosis clinicaltrials.gov\/study\/NCT00030966"},{"issue":"4","key":"10.1002\/14651858.CD015123.pub2-BIB0094|cit94","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/archneurol","article-title":"Efficacy of natalizumab therapy in patients of African descent with relapsing multiple sclerosis: analysis of AFFIRM and SENTINEL data","volume":"68","author":"Cree","year":"2011","journal-title":"Archives of Neurology"},{"issue":"16","key":"10.1002\/14651858.CD015123.pub2-BIB0095|cit95","doi-asserted-by":"publisher","first-page":"1299-304","DOI":"10.1212\/01.wnl.0000259521.14704.a8","article-title":"Natalizumab reduces visual loss in patients with relapsing multiple sclerosis","volume":"68","author":"Balcer","year":"2007","journal-title":"Neurology"},{"issue":"5","key":"10.1002\/14651858.CD015123.pub2-BIB0096|cit96","doi-asserted-by":"publisher","first-page":"898-905","DOI":"10.1007\/s00415-011-6275-7","article-title":"Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS","volume":"259","author":"Weinstock-Guttman","year":"2012","journal-title":"Journal of Neurology"},{"issue":"3","key":"10.1002\/14651858.CD015123.pub2-BIB0097|cit97","doi-asserted-by":"publisher","first-page":"405-15","DOI":"10.1007\/s00415-009-0093-1","article-title":"The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL","volume":"256","author":"Hutchinson","year":"2009","journal-title":"Journal of Neurology"},{"issue":"1","key":"10.1002\/14651858.CD015123.pub2-BIB0098|cit98","doi-asserted-by":"publisher","first-page":"55-60","DOI":"10.1136\/jnnp-2011-300279","article-title":"Treatment effect of natalizumab on relapse outcomes in multiple sclerosis patients despite ongoing MRI activity","volume":"83","author":"Bates","year":"2012","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD015123.pub2-BIB0099|cit99","doi-asserted-by":"publisher","first-page":"335-46","DOI":"10.1002\/ana.21163","article-title":"Health-related quality of life in multiple sclerosis: effects of natalizumab","volume":"62","author":"Rudick","year":"2007","journal-title":"Annals of Neurology"},{"issue":"14","key":"10.1002\/14651858.CD015123.pub2-BIB0100|cit100","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1212\/01.wnl.0000277457.17420.b5","article-title":"The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL","volume":"69","author":"Calabresi","year":"2007","journal-title":"Neurology"},{"issue":"1-2","key":"10.1002\/14651858.CD015123.pub2-BIB0101|cit101","doi-asserted-by":"publisher","first-page":"28-35","DOI":"10.1016\/j.jns.2010.02.012","article-title":"Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis","volume":"292","author":"Radue","year":"2010","journal-title":"Journal of the Neurological Sciences"},{"issue":"5","key":"10.1002\/14651858.CD015123.pub2-BIB0102|cit102","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S1474-4422(18)30069-3","article-title":"Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension","volume":"17","author":"Kapoor","year":"2018","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0103|cit103","unstructured":"A clinical study of the efficacy of natalizumab on reducing disability progression in participants with secondary progressive multiple sclerosis (ASCEND in SPMS) clinicaltrials.gov\/study\/NCT01416181"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0104|cit104","unstructured":"A clinical study of the efficacy of natalizumab on reducing disability progression in subjects with SPMS www.clinicaltrialsregister.eu\/ctr-search\/trial\/2010-021978-11\/results"},{"issue":"1","key":"10.1002\/14651858.CD015123.pub2-BIB0105|cit105","doi-asserted-by":"publisher","first-page":"e000240","DOI":"10.1136\/bmjno-2021-000240","article-title":"Chronic lesion activity and disability progression in secondary progressive multiple sclerosis","volume":"4","author":"Beynon","year":"2022","journal-title":"BMJ Neurology Open"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0106|cit106","doi-asserted-by":"publisher","first-page":"S59-60","DOI":"10.1002\/ana.24068","article-title":"Ascend study of natalizumab efficacy on disability in patients with secondary progressive multiple sclerosis (SPMS): baseline demographics and disease characteristics","volume":"74","author":"Mikol","year":"2013","journal-title":"Annals of Neurology"},{"issue":"16","key":"10.1002\/14651858.CD015123.pub2-BIB0107|cit107","doi-asserted-by":"publisher","first-page":"P5.330","DOI":"10.1212\/WNL.88.16_supplement.P5.330","article-title":"ASCEND phase 3 trial open-label extension study results: natalizumab may delay disability progression in secondary progressive multiple sclerosis (SPMS)","volume":"88","author":"Hartung","year":"2017","journal-title":"Neurology"},{"issue":"11","key":"10.1002\/14651858.CD015123.pub2-BIB0108|cit108","doi-asserted-by":"publisher","first-page":"507-8","DOI":"10.1177\/1352458513502429","article-title":"ASCEND study of natalizumab efficacy on reducing disability in patients with secondary progressive multiple sclerosis: baseline demographics and disease characteristics","volume":"19","author":"Mikol","year":"2013","journal-title":"Multiple Sclerosis Journal"},{"issue":"3","key":"10.1002\/14651858.CD015123.pub2-BIB0109|cit109","doi-asserted-by":"publisher","first-page":"36-7","DOI":"10.1177\/1352458517731283","article-title":"Natalizumab improves walking and upper-limb disability compared with placebo in patients with secondary progressive multiple sclerosis: an integrated, post hoc area under the outcome-time curve analysis from the ASCEND trial","volume":"23","author":"Giovannoni","year":"2017","journal-title":"Multiple Sclerosis Journal"},{"issue":"2","key":"10.1002\/14651858.CD015123.pub2-BIB0110|cit110","first-page":"e22","article-title":"Natalizumab versus placebo in patients with secondary progressive multiple sclerosis (SPMS): results from ASCEND, a multicenter, double-blind, placebo-controlled, randomized phase 3 clinical trial","volume":"87","author":"Steiner","year":"2016","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0111|cit111","doi-asserted-by":"publisher","first-page":"874-5","DOI":"10.1177\/1352458516664293","article-title":"Subgroup analyses of natalizumab treatment response in ASCEND, a multicenter, double-blind, placebo-controlled, randomized phase 3 clinical trial in patients with secondary progressive multiple sclerosis (SPMS)","volume":"22","author":"Kapoor","year":"2016","journal-title":"Multiple Sclerosis Journal"},{"issue":"16_supplement","key":"10.1002\/14651858.CD015123.pub2-BIB0112|cit112","doi-asserted-by":"publisher","first-page":"P5.359","DOI":"10.1212\/WNL.88.16_supplement.P5.359","article-title":"Sustained disability improvement as assessed by a multicomponent endpoint in secondary progressive multiple sclerosis (SPMS) patients: A post hoc analysis from ASCEND","volume":"88","author":"Giovannoni","year":"2017","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0113|cit113","doi-asserted-by":"publisher","first-page":"671-2","DOI":"10.1177\/1352458516663086","article-title":"Sustained disability improvement in patients with secondary progressive multiple sclerosis (SPMS) assessed by a multicomponent endpoint: a post hoc analysis from the ASCEND study","volume":"22","author":"Giovannoni","year":"2016","journal-title":"Multiple Sclerosis Journal"},{"issue":"3","key":"10.1002\/14651858.CD015123.pub2-BIB0114|cit114","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1001\/jamaneurol.2022.5007","article-title":"Efficacy and safety of proposed biosimilar natalizumab (PB006) in patients with relapsing-remitting multiple sclerosis: the antelope phase 3 randomized clinical trial","volume":"80","author":"Hemmer","year":"2023","journal-title":"JAMA Neurology"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0115|cit115","unstructured":"Efficacy and safety of the biosimilar natalizumab PB006 in comparison to tysabri\u00ae (antelope) clinicaltrials.gov\/study\/NCT04115488"},{"issue":"2_suppl","key":"10.1002\/14651858.CD015123.pub2-BIB0116|cit116","doi-asserted-by":"publisher","first-page":"757-8","DOI":"10.1177\/13524585211047080","article-title":"Efficacy and safety of proposed natalizumab biosimilar PB006 versus Tysabri\u00ae in patients with relapsing remitting multiple sclerosis: primary data from the phase III Antelope study","volume":"27","author":"Hemmer","year":"2021","journal-title":"Multiple Sclerosis Journal"},{"issue":"18\\_supplement","key":"10.1002\/14651858.CD015123.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1212\/WNL.98.18_supplement.1103","article-title":"Efficacy and safety of proposed natalizumab biosimilar PB006 versus Tysabri\u00ae in patients with relapsing remitting multiple sclerosis: primary data from the Phase III Antelope study","volume":"98","author":"Hemmer","year":"2022","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0118|cit118","unstructured":"A study of biosimilar Natalizumab in comparision to Tysabri in Patients with Multiple Sclerosis www.clinicaltrialsregister.eu\/ctr-search\/trial\/2018-004751-20\/results"},{"issue":"4","key":"10.1002\/14651858.CD015123.pub2-BIB0119|cit119","doi-asserted-by":"publisher","first-page":"170","DOI":"10.7224\/1537-2073.2019-131","article-title":"Perceptions and preferences regarding multiple sclerosis research among racial and ethnic groups","volume":"23","author":"Pimentel Maldonado","year":"2021","journal-title":"International Journal of MS Care"},{"issue":"3","key":"10.1002\/14651858.CD015123.pub2-BIB0120|cit120","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s40120-023-00461-0","article-title":"Long-term effectiveness and safety of natalizumab in African American and Hispanic\/Latino patients with early relapsing-remitting multiple sclerosis: STRIVE data analysis","volume":"12","author":"Perumal","year":"2023","journal-title":"Neurology and Therapy"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0121|cit121","doi-asserted-by":"publisher","first-page":"105153","DOI":"10.1016\/j.msard.2023.105153","article-title":"Ethnic disparities in the epidemiological and clinical characteristics of multiple sclerosis","volume":"81","author":"Mallawaarachchi","year":"2024","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"5","key":"10.1002\/14651858.CD015123.pub2-BIB0122|cit122","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1177\/1352458519887328","article-title":"Race and ethnicity on MS presentation and disease course","volume":"26","author":"Amezcua","year":"2020","journal-title":"Multiple Sclerosis Journal"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0123|cit123","doi-asserted-by":"publisher","first-page":"103760","DOI":"10.1016\/j.msard.2022.103760","article-title":"Impact of disease-modifying therapies on MRI outcomes in patients with relapsing -remitting multiple sclerosis: A systematic review and network meta-analysis","volume":"61","author":"Bose","year":"2022","journal-title":"Multiple Sclerosis and Related Disorders"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0124|cit124","doi-asserted-by":"publisher","first-page":"578178","DOI":"10.1016\/j.jneuroim.2023.578178","article-title":"Disease modifying therapy and pregnancy outcomes in multiple sclerosis: A systematic review and meta-analysis","volume":"383","author":"Khan","year":"2023","journal-title":"Journal of Neuroimmunology"},{"issue":"11","key":"10.1002\/14651858.CD015123.pub2-BIB0125|cit125","doi-asserted-by":"publisher","first-page":"e051509","DOI":"10.1136\/bmjopen-2021-051509","article-title":"Impact of disease-modifying therapies on MRI and neurocognitive outcomes in relapsing-remitting multiple sclerosis: a protocol for a systematic review and network meta-analysis","volume":"11","author":"Lees","year":"2021","journal-title":"BMJ Open"},{"issue":"6","key":"10.1002\/14651858.CD015123.pub2-BIB0126|cit126","doi-asserted-by":"publisher","first-page":"102826","DOI":"10.1016\/j.autrev.2021.102826","article-title":"Disease modifying therapies in relapsing-remitting multiple sclerosis: A systematic review and network meta-analysis","volume":"20","author":"Liu","year":"2021","journal-title":"Autoimmunity Reviews"},{"issue":"6","key":"10.1002\/14651858.CD015123.pub2-BIB0127|cit127","doi-asserted-by":"publisher","first-page":"480","DOI":"10.5603\/PJNNS.a2022.0068","article-title":"Systematic review and network meta-analysis (NMA) for cladribine tablets in achieving sustained disability improvement (SDI) in multiple sclerosis","volume":"56","author":"Piasecka-Stryczy\u0144ska","year":"2022","journal-title":"Neurologia I Neurochirurgia Polska"},{"issue":"7","key":"10.1002\/14651858.CD015123.pub2-BIB0128|cit128","doi-asserted-by":"publisher","first-page":"e230016","DOI":"10.57264\/cer-2023-0016","article-title":"Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis","volume":"12","author":"Samjoo","year":"2023","journal-title":"Journal of Comparative Effectiveness Research"},{"issue":"5","key":"10.1002\/14651858.CD015123.pub2-BIB0129|cit129","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/ane.13697","article-title":"Is there a role for off-label high-efficacy disease-modifying drugs in progressive multiple sclerosis? A network meta-analysis","volume":"146","author":"Silva","year":"2022","journal-title":"Acta Neurologica Scandinavica"},{"issue":"9","key":"10.1002\/14651858.CD015123.pub2-BIB0130|cit130","doi-asserted-by":"publisher","first-page":"5479","DOI":"10.1007\/s10072-022-06197-3","article-title":"Comparative safety of high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis","volume":"43","author":"\u015aladowska","year":"2022","journal-title":"Neurological Sciences"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0131|cit131","doi-asserted-by":"publisher","first-page":"577721","DOI":"10.1016\/j.jneuroim.2021.577721","article-title":"Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: A systematic review and meta-analysis","volume":"360","author":"Sriwastava","year":"2021","journal-title":"Journal of Neuroimmunology"},{"key":"10.1002\/14651858.CD015123.pub2-BIB0132|cit132","doi-asserted-by":"publisher","first-page":"1295770","DOI":"10.3389\/fneur.2024.1295770","article-title":"Disease-modifying therapy in progressive multiple sclerosis: a systematic review and network meta-analysis of randomized controlled trials","volume":"15","author":"Wu","year":"2024","journal-title":"Frontiers in Neurology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:32:33Z","timestamp":1788435153000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD015123.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":132,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd015123.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]}}}